Oculis (NASDAQ:OCS) Announces Quarterly Earnings Results

Oculis (NASDAQ:OCS) announced its quarterly earnings results on Monday. The company reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.14), Zacks reports. The company had revenue of $0.26 million during the quarter, compared to the consensus estimate of $0.25 million. Oculis had a negative net margin of 8,460.67% and a negative return on equity of 61.23%.

Oculis Stock Performance

NASDAQ OCS opened at $30.41 on Wednesday. The firm’s fifty day moving average price is $27.20 and its two-hundred day moving average price is $24.40. The stock has a market cap of $1.76 billion, a PE ratio of -14.28 and a beta of 0.38. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.96 and a current ratio of 5.96. Oculis has a fifty-two week low of $16.00 and a fifty-two week high of $34.47.

Institutional Investors Weigh In On Oculis

Institutional investors have recently added to or reduced their stakes in the business. SR One Capital Management LP lifted its holdings in shares of Oculis by 98.8% during the fourth quarter. SR One Capital Management LP now owns 641,022 shares of the company’s stock worth $12,801,000 after purchasing an additional 318,522 shares during the period. Perceptive Advisors LLC acquired a new stake in Oculis in the fourth quarter valued at $9,862,000. Alyeska Investment Group L.P. lifted its holdings in Oculis by 152.3% during the 4th quarter. Alyeska Investment Group L.P. now owns 331,332 shares of the company’s stock worth $6,617,000 after buying an additional 200,000 shares during the period. Woodline Partners LP lifted its holdings in Oculis by 65.8% during the 3rd quarter. Woodline Partners LP now owns 83,833 shares of the company’s stock worth $1,474,000 after buying an additional 33,265 shares during the period. Finally, Alps Advisors Inc. bought a new stake in shares of Oculis in the 4th quarter valued at about $938,000. 22.30% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

OCS has been the subject of several recent analyst reports. HC Wainwright upped their price objective on shares of Oculis from $44.00 to $47.00 and gave the stock a “buy” rating in a research report on Tuesday. Wall Street Zen cut shares of Oculis from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oculis in a report on Tuesday, April 21st. Stifel Nicolaus lifted their price objective on shares of Oculis from $40.00 to $50.00 and gave the company a “buy” rating in a research note on Wednesday, March 4th. Finally, Needham & Company LLC boosted their price objective on shares of Oculis from $40.00 to $46.00 and gave the company a “buy” rating in a research report on Tuesday. Seven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $45.14.

Oculis Company Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.